Approaches to Individualized Management of Patients with Myeloproliferative Neoplasms: Best Practices and Guidance to Optimize Care
  • CME

Watch this CME-certified on-demand Webcast of a CCO live symposium from ASH 2019 to gain insights from the experts on best practices for the individualized care of patients with myeloproliferative neoplasms.
Srdan Verstovsek, MD, PhD
Program Director
Jean-Jacques Kiladjian, MD, PhD
Raajit K. Rampal, MD, PhD
Alessandro M. Vannucchi, MD
Physicians: maximum of 2.5 AMA PRA Category 1 Credits
Released: January 17, 2020 Expiration: January 16, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Select optimal, individualized treatment for patients with MPNs based on recent advances and evolving best practices to maximize clinical outcomes
  • Integrate emerging agents and regimens for MPNs into routine practice as clinically appropriate
  • Develop an evidence-based treatment plan to improve outcomes in the treatment of MPNs
  • Develop strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion
  • Refer appropriate patients with MPNs to select ongoing clinical trials of novel agents and strategies

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director

Srdan Verstovsek, MD, PhD

Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has disclosed that he has received consulting fees from Celgene, Constellation, Incyte, Novartis, Sierra, and Pragmatist, and funds for research support from Blueprint Medicines Corp., Celgene, CTI BioPharma Corp., Genentech, Gilead, Incyte Corp., Novartis, NS Pharma, Promedior and Roche.


Jean-Jacques Kiladjian, MD, PhD

Department of Clinical Pharmacology
Université de Paris
Clinical Investigations Center
Saint-Louis Hospital
Paris, France

Jean-Jacques Kiladjian, MD, PhD, has disclosed that he has received consulting fees from AOP Orphan, Celgene, and Novartis, and funds for contracted research from Novartis.
Raajit K. Rampal, MD, PhD

Assistant Member
Assistant Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit Rampal, MD, PhD, has disclosed that he has received consulting fees from Beyond Spring, Celgene, Constellation, Jazz, Partner Therapeutics, and Stemline and contracted research fees from Constellation and Stemline.
Alessandro M. Vannucchi, MD

Full Professor of Hematology
Department of Experimental and Clinical Medicine
University of Florence
Center of Research and Innovation of Myeloproliferative Neoplasms
AOU Careggi
Florence, Italy

Alessandro M. Vannucchi, MD disclosed that he has received consulting fees from Incyte and Novartis, and fees for non-CME/CE services from Celgene.


Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians and other healthcare providers who treat and manage patients with myeloproliferative neoplasms.


The goal of this activity is to improve participants’ knowledge of and competence in integrating new agents into the treatment of patients with myeloproliferative neoplasms.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 17, 2020, through January 16, 2021:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert answers to key questions on the current treatment of myeloproliferative neoplasms from a Clinical Care Options (CCO) symposium at ASH 2019

Srdan Verstovsek, MD, PhD
Program Director
Jean-Jacques Kiladjian, MD, PhD Raajit K. Rampal, MD, PhD Alessandro M. Vannucchi, MD
Released: January 16, 2020

Data on venetoclax with or without azacitidine in patients with relapsed/refractory MDS from ASH 2019 as reported by Clinical Care Options (CCO)

Released: December 19, 2019

From Clinical Care Options, download slides reviewing the optimal management of MPNs.

Prithviraj Bose, MD Stephen Oh, MD, PhD Released: December 19, 2019

In this slideset from Clinical Care Options, experts provide insights on best practice for managing patients with PV and ET.

Jean-Jacques Kiladjian, MD, PhD Released: December 6, 2019
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Celgene Corporation
CTI Biopharma

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?